We demonstrated an association between elevated IGF2BP3 expression and metastasis, as well as a marginal association with adverse disease-specific survival in MCC, which aligns with similar observations in diverse cancer types, including melanoma (Hanniford et al, 2020; Sheen et al, 2015), breast cancer (Jiang et al, 2022), nasopharyngeal carcinoma (Du et al, 2022; Xu et al, 2022), pancreatic cancer (Taniuchi et al, 2014), prostate cancer (Yu et al, 2022), Ewing sarcoma (Mancarella et al, 2020), and bladder cancer (Liu et al, 2022). Here, IGF2BP3 is linked to breast carcinoma.